Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pouwels, M.-J. J.
Right arrow Articles by Hermus, A. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pouwels, M.-J. J.
Right arrow Articles by Hermus, A. R.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 26:1637-1639, 2003
© 2003 by the American Diabetes Association, Inc.

Letters: Observations
Letter

Improved Insulin Sensitivity and Metabolic Control in Type 2 Diabetes Does Not Influence Plasma Homocysteine

Marie-Jose J. Pouwels, MD1,2, Martin den Heijer, MD, PHD1, Henk J. Blom, PHD3, Cees J. Tack, MD, PHD1,2 and Ad R. Hermus, MD, PHD1

1 Department of Endocrinology, University Medical Center Nijmegen, the Netherlands
2 Department of General Internal Medicine, University Medical Center Nijmegen, the Netherlands
3 Laboratory of Pediatrics and Neurology, University Medical Center Nijmegen, the Netherlands

Type 2 diabetes is characterized by both insulin resistance and an increased cardiovascular mortality (1). Elevated plasma total homocysteine levels are an independent risk factor for cardiovascular disease (2). Also, in patients with type 2 diabetes, elevated plasma total homocysteine levels are associated with an increased risk of cardiovascular disease and an increased mortality (3,4).

It is well known that insulin resistance is aggravated by chronic hyperglycemia. This hyperglycemia-induced insulin resistance is reversed by treatment, resulting in a prolonged period of euglycemia (5).

Although in animal studies evidence was found that hyperinsulinemia and/or insulin resistance increased total homocysteine levels (6), in humans the relation between insulin resistance and total homocysteine levels is unclear, in both healthy subjects (7–12) and patients with type 2 diabetes (13–16). In patients with type 2 diabetes, a positive association between insulin resistance and total homocysteine levels was reported (13), but this finding was not reproduced (14). Furthermore, in patients with type 2 diabetes, a positive association between the degree of metabolic control and total homocysteine levels was reported (15,16).

We hypothesized that if insulin resistance is associated with elevated homocysteine levels, thereby providing another explanation for the increased cardiovascular disease in type 2 diabetes, then homocysteine levels will decrease after amelioration of hyperglycemia-induced insulin resistance and associated metabolic abnormalities.

Here, we report the results of an intervention study (17). Eight obese type 2 diabetic patients (aged 53 ± 13 years, HbA1c 12.0 ± 1.7%, BMI 38 ± 5.8 kg/m2) with severe insulin resistance (subcutaneous insulin dose, four-dose insulin regimen 1.92 ± 0.66 units · kg-1 · day-1) were studied before and after a period of 28 ± 5 days of intravenous insulin treatment. Intravenous insulin treatment resulted in euglycemia. Before and after intervention, insulin sensitivity was assessed by a hyperinsulinemic-euglycemic clamp. Fasting plasma total homocysteine, HbA1c, and lipid concentrations were measured on the days of the clamps. Also, 24-h urine creatinine excretion was investigated before and after intervention.

Plasma total homocysteine levels were measured with a high-performance liquid chromatography method according to Fiskerstrand (18,19) with some modifications. Because all variables were normally distributed, statistical analyses of differences were performed by paired Student’s t test. P < 0.05 was considered significant. Results are given as the mean ± SD.

After a 4-week period of intravenous insulin treatment resulting in an euglycemic period of 17 ± 4 days, insulin sensitivity improved since body glucose uptake, measured by clamp, increased (12.7 ± 5.7 before vs. 22.4 ± 8.8 µmol · kg-1 · min-1 after euglycemia, P < 0.0005) and the intravenous insulin dose required for achieving and maintaining euglycemia decreased (1.7 ± 0.9 before vs. 1.1 ± 0.6 units · kg-1 · day-1 after euglycemia, P < 0.005). Metabolic control improved; HbA1c decreased substantially (12.0 ± 1.7 before vs. 8.9 ± 1.2% after euglycemia, P < 0.0001); total cholesterol decreased (5.40 ± 1.09 before vs. 4.50 ± 1.10 mmol/l after euglycemia, P < 0.05); and triglycerides tended to decrease (4.34 ± 3.32 before vs. 1.91 ± 0.69 mmol/l after euglycemia, P = 0.06). These results are described in detail elsewhere (17). Plasma total homocysteine levels were similar before and after improved insulin sensitivity (total homocysteine levels 8.5 ± 2.4 before vs. 9.2 ± 3.5 µmol/l after euglycemia, P = 0.5). Urine creatinine excretion was similar before and after euglycemia (15.0 ± 4.8 before vs. 12 ± 4.3 µmol/24 h after euglycemia).

This intervention study shows that despite amelioration of hyperglycemia-induced insulin resistance and improved metabolic control, plasma total homocysteine concentrations did not decrease. Homocysteine levels, measured in these patients with type 2 diabetes, were actually within the normal range of healthy subjects (2).

Our study is the first intervention study to investigate the relation between insulin resistance and plasma total homocysteine levels. To date only cross-sectional studies have been performed (13–15), which are more susceptible for confounding by other metabolic factors. Also in contrast to previous reports (8,9,11,12,14,15), we studied insulin sensitivity by clamp, the gold standard.

We conclude that amelioration of hyperglycemia-induced insulin resistance does not change plasma total homocysteine levels. These data refute the hypothesis that homocysteine levels are influenced by insulin resistance and by the degree of metabolic control, at least in the patients we studied. Therefore, these results do not support elevated homocysteine levels as an explanation for the link between insulin resistance and the increased risk of cardiovascular disease in type 2 diabetes.

Acknowledgments

This study was supported by a grant from the Dutch Diabetes Foundation. H.J.B. is an established investigator of the Netherlands Heart Foundation (D97.021).

Footnotes

Address correspondence to Marie-Jose Pouwels, MD, Division of General Internal Medicine, Medisch Spectrum Twente, P.O. Box 50000, 7500 KA Enschede, The Netherlands. E-mail: m.j.pouwels{at}club.tip.nl.

References

  1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234, 1998[Abstract/Free Full Text]
  2. Welch GN, Loscalzo J: Homocysteine and atherothrombosis. N Engl J Med 338:1042–1050, 1998[Free Full Text]
  3. Hoogeveen EK, Kostense PJ, Beks PJ, Mackaay AJC, Jakobs C, Bouter LM, Heine RJ, Stehouwer CD: Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol 18:133–138, 1998[Abstract/Free Full Text]
  4. Hoogeveen EK, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD: Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the hoorn study. Circulation 101:1506–1511, 2000[Abstract/Free Full Text]
  5. Rossetti L: Glucose toxicity. Clin Invest Med 18:255–260, 1995[Medline]
  6. Fonseca V, Dicker-Brown A, Ranganathan S, Song W, Barnard RJ, Fink L, Kern PA: Effects of a high-fat-sucrose diet on enzymes in homocysteine metabolism in the rat. Metabolism 49:736–741, 2000[Medline]
  7. Giltay EJ, Hoogeveen EK, Elber JM, Gooren LJ, Asscheman H, Stehouwer CE: Insulin resistance is associated with elevated plasma total homocysteine levels in healthy, non-obese subjects. Atherosclerosis 139:197–198, 1998[Medline]
  8. Meigs JB, Jacques PF, Selhub J, Singer DE, Nathan DM, Rifai N, D’Agostino RB Sr, Wilson PW: Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study. Diabetes Care 24:1403–1410, 2001[Abstract/Free Full Text]
  9. De Pergola G, Pannacciulli n, Zamboni M, Minenna A, Brocco G, Sciaraffia M, Bosello, Giorgino R: Homocysteine plasma levels are independently associated with insulin resistance in normal weight, overweight and obese pre-menopausal women. Diabetes Nutr Metab 14:253–258, 2001[Medline]
  10. Abbasi F, Facchini F, Humphreys MH, Reaven GM: Plasma homocysteine concentrations in healthy volunteers are not related to differences in insulin-mediated glucose disposal. Atherosclerosis 146:175–178, 1999[Medline]
  11. Bar-on H, Kidron M, Friedlander Y, Ben-Yehuda A, Selhub J, Rosenberg IH, Friedman G: Plasma total homocysteine levels in subjects with hyperinsulinemia. J Intern Med 247:287–294, 2000[Medline]
  12. Godsland IF, Rosankiewicz JR, Proudler AJ, Johnston DG: Plasma total homocysteine concentrations are unrelated to insulin sensitivity and components of the metabolic syndrome in healthy men. J Clin Endocrinol Metab 86:719–723, 2001[Abstract/Free Full Text]
  13. Emoto M, Kanda H, Shoji T, Kawagishi T, Komatsu M, Mori K, Tahara H, Ishimura E, Inaba M, Okuno Y, Nishizawa Y: Impact of insulin resistance and nephropathy on homocysteine in type 2 diabetes. Diabetes Care 24:533–538, 2001[Abstract/Free Full Text]
  14. Buysschaert M, Dramais AS, Wallemacq PE, Hermans MP: Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care 23:1816–1822, 2000[Abstract/Free Full Text]
  15. Drzewoski J, Czupryniak L, Chwatko G, Bald E: Total plasma homocysteine and insulin levels in type 2 diabetic patients with secondary failure to oral agents. Diabetes Care 22:2097–2098, 1999[Free Full Text]
  16. Chan NN: Homocysteine and insulin levels in type 2 diabetic patients (Letter). Diabetes Care 23:1041, 2000[Medline]
  17. Pouwels MJ, Tack CJ, Hermus AR, Lutterman JA: Treatment with intravenous insulin followed by continuous subcutaneous insulin infusion improves glycemic control in severely resistant type 2 diabetic patients. Diabet Med 20:76–79, 2003[Medline]
  18. Fiskerstrand T, Refsum H, Kvalheim G, Ueland PM: Homocysteine and other thiols in plasma and urine: automated determination and sample stability. Clin Chem 39:263–271, 1993[Abstract]
  19. te Poele-Pothoff MT, van der Berg M, Franken DG, Boers GH, Jacobs C, de Kroon IF, Eskes TK, Trijbels JM, Blom HJ: Three different methods for the determination of total homocysteine in plasma. Ann Clin Biochem 32:218–220, 1995

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
W. E. Rodriguez, I. G. Joshua, J. C. Falcone, and S. C. Tyagi
Pioglitazone prevents cardiac remodeling in high-fat, high-calorie-induced Type 2 diabetes mellitus
Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H81 - H87.
[Abstract] [Full Text] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
S. C. Tyagi, W. Rodriguez, A. M. Patel, A. M. Roberts, J. C. Falcone, J. C. Passmore, J. T. Fleming, and I. G. Joshua
Hyperhomocysteinemic Diabetic Cardiomyopathy: Oxidative Stress, Remodeling, and Endothelial-Myocyte Uncoupling
Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2005; 10(1): 1 - 10.
[Abstract] [PDF]

This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pouwels, M.-J. J.
Right arrow Articles by Hermus, A. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pouwels, M.-J. J.
Right arrow Articles by Hermus, A. R.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum